The Executive Director, Brand Lead – Endometrial Cancer (EC) is a senior commercial leader responsible for U.S. brand strategy, launch readiness, performance planning, and lifecycle management for Karyopharm’s EC program. This is a unique opportunity to shape the U.S. commercial strategy for a potential new treatment approach in endometrial cancer at a pivotal moment for Karyopharm. The Brand Lead will help translate late-stage science into a launch-ready commercial strategy, build the market with urgency and discipline, and lead cross-functional efforts focused on improving outcomes for patients with advanced or recurrent endometrial cancer.
The Executive Director will operate as the commercial lead for the EC disease area, driving alignment across Sales, Marketing, Market Access, Market Analytics, Regulatory, Legal, Commercial Operations, Medical Affairs, and Finance. This individual will shape long-term strategic direction while establishing the launch priorities, operating discipline, and cross-functional execution required to prepare the organization for a high-quality U.S. launch.
Operating in a lean biotech environment, the Brand Lead will bring strategic clarity, decisive leadership, and strong enterprise collaboration to ensure the organization is field-ready, access-ready, customer-ready, and evidence-aligned to establish a differentiated position in the evolving gynecologic oncology landscape
RESPONSIBILITIES:
QUALIFICATIONS:
At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $270K - $315K USD.
This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.
Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.
As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.
Learn more at Karyopharm Therapeutics.
Software Powered by iCIMS
www.icims.com